Beta-1 selective beta blocker
Antianginal agent
Antihypertensive
CCP: Symptomatic atrial fibrillation or atrial flutter with rapid ventricular response
CCP: Symptomatic atrial fibrillation or atrial flutter with rapid ventricular response
MetoPROLOL has a preferential inhibitory effect on beta-1 adrenoreceptors, located primarily in the cardiac muscle. At higher doses, metoPROLOL can exert some inhibition on beta-2 receptors in bronchial and vascular tissues.
Intravenous:
Provide supportive care. Review J07: Beta Blockers Toxicity for specific guidance.
MetoPROLOL should be used with caution in compensated heart failure; patients must be closely monitored for worsening of their condition.